Evidence map›Paper›PMID 26579461›Full record

ArticleActa pharmaceutica Sinica. B2015

Development of a C3c-based ELISA method for the determination of anti-complementary potency of Bupleurum polysaccharides.

Mulu Wu, Hong Li, Yunyi Zhang, Daofeng Chen

Open access · diamondAbstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Beneficial effects ofActa pharmaceutica Sinica. B · 2018
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mulu WuDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China.
Hong LiDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China.
Yunyi ZhangDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201203, China.
Daofeng ChenDepartment of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai 201203, China.
Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traditionally, determination of inhibitory potency of complement inhibitors is performed by the hemolytic assay. However, this assay is not applicable to the lectin pathway, thus impeding the understanding of complement inhibitors against the overall function of the complement system. The main objective of our study was to develop a specific enzyme-linked immunosorbent assay (ELISA) as an alternative method to assess the anti-complement activity, particularly against the lectin pathway. By using respective coating substrates against different activation pathways, followed by capturing the stable C3c fragments, our ELISA method can be used to screen complement inhibitors against the classical pathway and the lectin pathway. The inhibitory effect of suramin on the classical pathway, as measured by our hemolytic assay is consistent with previous reports. Further assessment of suramin and Bupleurum polysaccharides against the lectin pathway showed a good reproducibility of the method. Comparison of the lectin pathway IC50 between Bupleurum smithii var. parvifolium polysaccharides (1.055 mg/mL) and Bupleurum chinense polysaccharides (0.98 mg/mL) showed that, similar to the classical and alterative pathway, these two Bupleurum polysaccharides had comparable anti-complementary properties against the lectin pathway. The results demonstrate that the described ELISA assay can compensate for the shortcomings of the hemolytic assay in lectin pathway.

Indexed as

Abs, antibodiesAP, alternative pathwayBCPs, Bupleurum chinense polysaccharidesBG, background valueBPs, Bupleurum smithii var. parvifolium polysaccharidesBSA, bovine serum albuminBupleurum chinenseBupleurum smithii var.  parvifoliumComplement C3cCP, classical pathwayCV, coefficient of variationDFC, drug-free controlELISAELISA, enzyme-linked immunosorbent assayHRP, horseradish peroxidesLP, lectin pathwayLPS, lipopolysaccharideMASP, MBL-associated serine proteasesMBL, mannose-binding lectinOD, optical densityPBS-T-BSA, PBS containing 0.05% Tween-20 and 1% BSAPolysaccharidesSRBC, sheep erythrocytesSuraminVBS, Veronal buffer saline

Identifiers

PMID26579461
PMCPMC4629277
OpenAlexW2018152347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.